GLOBEIMMUNE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -99.00% |
|
-.--% | -.--% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2014 | 5.97M 498M | Sales 2015 | 6.46M 539M | Capitalization | 22.26M 1.86B |
|---|---|---|---|---|---|
| Net income 2014 | -16M -1.34B | Net income 2015 | -2M -167M | EV / Sales 2014 | 4.5 x |
| Net cash position 2014 | 16.81M 1.4B | Net cash position 2015 | 9.9M 826M | EV / Sales 2015 | 1.91 x |
| P/E ratio 2014 |
-0.94
x | P/E ratio 2015 |
-8.04
x | Employees | 3 |
| Yield 2014 * |
-
| Yield 2015 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 day | -99.00% |
Current year
0.00
0.00
1 year
0.000.00
3 years
0.001.92
5 years
0.005.46
10 years
0.0015.00
| Members of the board | Title | Age | Since |
|---|---|---|---|
Augustine Lawlor
BRD | Director/Board Member | 67 | 01/03/01 |
Ehud Geller
BRD | Director/Board Member | 77 | - |
Charles C. Kim
BRD | Director/Board Member | - | - |
GlobeImmune Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Companyâs Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. It has over two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The Company's oncology product candidates include GI-6301, GI-6207 and GI-4000. The Company's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 5 | |
| +10.44% | 107B | |
| +0.82% | 106B | |
| +6.72% | 23.47B | |
| -13.89% | 21.9B | |
| -6.64% | 18.77B | |
| -37.26% | 17.85B | |
| -10.98% | 16.78B | |
| +8.67% | 14.41B | |
| +41.08% | 12.86B |
- Stock Market
- Equities
- GBIM Stock